Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TNRC6B

Gene summary for TNRC6B

Gene summary.

Gene information	Species	Human
	Gene symbol	TNRC6B
	Gene ID	23112
	Gene name	trinucleotide repeat containing adaptor 6B
	Gene Alias	GDSBA
	Cytomap	22q13.1
	Gene Type	protein-coding
	GO ID	GO:0000288
	UniProtAcc	A0A024R1N5

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23112	TNRC6B	CA_HPV_1	Human	Cervix	CC	3.26e-03	-5.85e-03	0.0264
23112	TNRC6B	CA_HPV_3	Human	Cervix	CC	2.78e-04	6.75e-02	0.0414
23112	TNRC6B	CCI_2	Human	Cervix	CC	8.12e-12	1.04e+00	0.5249
23112	TNRC6B	CCI_3	Human	Cervix	CC	4.62e-12	1.05e+00	0.516
23112	TNRC6B	CCII_1	Human	Cervix	CC	1.52e-02	-3.79e-01	0.3249
23112	TNRC6B	Tumor	Human	Cervix	CC	1.80e-02	-2.77e-01	0.1241
23112	TNRC6B	T3	Human	Cervix	CC	5.99e-06	-2.68e-01	0.1389
23112	TNRC6B	HTA11_3410_2000001011	Human	Colorectum	AD	1.34e-19	-4.89e-01	0.0155
23112	TNRC6B	HTA11_347_2000001011	Human	Colorectum	AD	2.54e-12	6.08e-01	-0.1954
23112	TNRC6B	HTA11_8622_2000001021	Human	Colorectum	SER	4.89e-04	-3.80e-01	0.0528
23112	TNRC6B	HTA11_6818_2000001021	Human	Colorectum	AD	1.23e-04	-4.45e-01	0.0588
23112	TNRC6B	HTA11_99999970781_79442	Human	Colorectum	MSS	1.22e-05	-3.19e-01	0.294
23112	TNRC6B	HTA11_99999965062_69753	Human	Colorectum	MSI-H	1.11e-02	6.74e-01	0.3487
23112	TNRC6B	HTA11_99999974143_84620	Human	Colorectum	MSS	1.07e-18	-5.32e-01	0.3005
23112	TNRC6B	F007	Human	Colorectum	FAP	2.69e-02	-1.48e-01	0.1176
23112	TNRC6B	A001-C-207	Human	Colorectum	FAP	1.09e-02	-1.64e-01	0.1278
23112	TNRC6B	A015-C-203	Human	Colorectum	FAP	8.03e-42	-5.32e-01	-0.1294
23112	TNRC6B	A015-C-204	Human	Colorectum	FAP	1.28e-05	-3.10e-01	-0.0228
23112	TNRC6B	A014-C-040	Human	Colorectum	FAP	1.81e-05	-5.12e-01	-0.1184
23112	TNRC6B	A002-C-201	Human	Colorectum	FAP	6.04e-13	-3.17e-01	0.0324

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00002888	Prostate	BPH	nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay	19/3107	56/18723	1.19e-03	7.31e-03	19
GO:20006375	Prostate	BPH	positive regulation of gene silencing by miRNA	12/3107	30/18723	1.94e-03	1.10e-02	12
GO:00601485	Prostate	BPH	positive regulation of posttranscriptional gene silencing	12/3107	31/18723	2.69e-03	1.43e-02	12
GO:00609684	Prostate	BPH	regulation of gene silencing	23/3107	81/18723	5.35e-03	2.49e-02	23
GO:000641719	Prostate	Tumor	regulation of translation	161/3246	468/18723	1.55e-19	8.74e-17	161
GO:190331117	Prostate	Tumor	regulation of mRNA metabolic process	111/3246	288/18723	6.66e-18	2.30e-15	111
GO:000989619	Prostate	Tumor	positive regulation of catabolic process	155/3246	492/18723	5.62e-15	8.52e-13	155
GO:000640217	Prostate	Tumor	mRNA catabolic process	87/3246	232/18723	1.56e-13	1.73e-11	87
GO:003133119	Prostate	Tumor	positive regulation of cellular catabolic process	134/3246	427/18723	5.54e-13	5.84e-11	134
GO:000640117	Prostate	Tumor	RNA catabolic process	94/3246	278/18723	1.77e-11	1.25e-09	94
GO:000095615	Prostate	Tumor	nuclear-transcribed mRNA catabolic process	46/3246	112/18723	2.80e-09	1.17e-07	46
GO:006101315	Prostate	Tumor	regulation of mRNA catabolic process	57/3246	166/18723	8.79e-08	2.39e-06	57
GO:003465516	Prostate	Tumor	nucleobase-containing compound catabolic process	112/3246	407/18723	1.61e-07	4.02e-06	112
GO:004348815	Prostate	Tumor	regulation of mRNA stability	54/3246	158/18723	2.26e-07	5.42e-06	54
GO:003424912	Prostate	Tumor	negative regulation of cellular amide metabolic process	80/3246	273/18723	6.33e-07	1.32e-05	80
GO:004670014	Prostate	Tumor	heterocycle catabolic process	117/3246	445/18723	1.11e-06	2.10e-05	117
GO:004427015	Prostate	Tumor	cellular nitrogen compound catabolic process	118/3246	451/18723	1.30e-06	2.39e-05	118
GO:004348715	Prostate	Tumor	regulation of RNA stability	54/3246	170/18723	3.00e-06	4.95e-05	54
GO:190331314	Prostate	Tumor	positive regulation of mRNA metabolic process	41/3246	118/18723	3.86e-06	6.18e-05	41
GO:001714812	Prostate	Tumor	negative regulation of translation	71/3246	245/18723	4.08e-06	6.51e-05	71

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

TNRC6B

SNV

Missense_Mutation

c.4778G>T

p.Arg1593Met

p.R1593M

Q9UPQ9

protein_coding

deleterious(0)

probably_damaging(0.987)

TCGA-A2-A04P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

taxol

TNRC6B

SNV

Missense_Mutation

c.872N>T

p.Asp291Val

p.D291V

Q9UPQ9

protein_coding

deleterious(0.01)

possibly_damaging(0.522)

TCGA-A2-A04U-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

TNRC6B

SNV

Missense_Mutation

c.1277N>T

p.Gly426Val

p.G426V

Q9UPQ9

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-A2-A0YC-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

TNRC6B

SNV

Missense_Mutation

c.4130N>T

p.Ser1377Phe

p.S1377F

Q9UPQ9

protein_coding

tolerated(0.48)

probably_damaging(0.988)

TCGA-A7-A26H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

TNRC6B

SNV

Missense_Mutation

novel

c.4237N>A

p.Glu1413Lys

p.E1413K

Q9UPQ9

protein_coding

deleterious(0)

benign(0.036)

TCGA-A8-A096-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

TNRC6B

SNV

Missense_Mutation

rs772135186

c.1769N>A

p.Arg590His

p.R590H

Q9UPQ9

protein_coding

deleterious(0.05)

probably_damaging(0.984)

TCGA-AN-A0XU-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

TNRC6B

SNV

Missense_Mutation

rs267606255

c.79N>A

p.Glu27Lys

p.E27K

Q9UPQ9

protein_coding

tolerated(0.14)

benign(0.015)

TCGA-B6-A0I5-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

TNRC6B

SNV

Missense_Mutation

rs267606255

c.79N>A

p.Glu27Lys

p.E27K

Q9UPQ9

protein_coding

tolerated(0.14)

benign(0.015)

TCGA-B6-A1KI-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

TNRC6B

SNV

Missense_Mutation

c.769N>A

p.Gly257Arg

p.G257R

Q9UPQ9

protein_coding

deleterious(0.03)

probably_damaging(0.998)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

TNRC6B

SNV

Missense_Mutation

rs778520882

c.5N>A

p.Arg2Lys

p.R2K

Q9UPQ9

protein_coding

tolerated_low_confidence(0.08)

benign(0.267)

TCGA-C8-A8HQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1